human breast cancer cell line bt 474 (ATCC)


Structured Review

Human Breast Cancer Cell Line Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell line bt 474/product/ATCC
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody"
Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
Journal: mAbs
doi: 10.1080/19420862.2018.1486946

Figure Legend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
Techniques Used: Activity Assay
human breast cancer cell line bt 474 (ATCC)


Structured Review

Human Breast Cancer Cell Line Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell line bt 474/product/ATCC
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody"
Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
Journal: mAbs
doi: 10.1080/19420862.2018.1486946

Figure Legend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
Techniques Used: Activity Assay
human breast cancer cell lines bt 474 (ATCC)


Structured Review

Human Breast Cancer Cell Lines Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell lines bt 474/product/ATCC
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells"
Article Title: Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
Journal: International Journal of Nanomedicine
doi: 10.2147/IJN.S144184

Figure Legend Snippet: Expression of HER2 in breast cancer cells, analyzed by flow cytometry. Notes: Representative fluorescence-activated cell sorting analysis of ( A ) MDA-MB-361 and ( B ) BT-474 cells tested by ALDEFLUOR assay. In the right image (ALDH+ DEAB), cells incubated with ALDH substrate (BAAA) and the specific inhibitor of ALDH, DEAB, were used to establish the baseline fluorescence of these cells (R1) and to define the ALDEFLUOR-positive region (R2). ( C ) Percentage of HER2 positively stained cells in breast cancer cells. ( D ) HER2 mean fluorescence intensity in breast cancer cells. Data are expressed as mean ± SD (n=3). ** P <0.01. Abbreviations: ALDH, aldehyde dehydrogenase; BAAA, BODIPY-aminoacetaldehyde; DEAB, diethylaminobenzaldehyde.
Techniques Used: Expressing, Flow Cytometry, Fluorescence, FACS, Incubation, Staining

Figure Legend Snippet: Cell proliferation assay. Notes: ALDH+ and ALDH− breast cancer cells were seeded in 96-well plates with a density of 1×10 4 cells per well overnight. The cells were incubated with the nanoparticles or salinomycin for 72 h, and cell viability was evaluated using the CCK-8 assay. ( A ) MDA-MB-361 ALDH+, ( B ) MDA-MB-361 ALDH−, ( C ) BT-474 ALDH+, and ( D ) BT-474 ALDH−. Data are expressed as mean ± SD (n=3). Abbreviations: ALDH, aldehyde dehydrogenase; CCK-8, Cell Counting Kit-8; Sali-NP, salinomycin-loaded polymer-lipid nanoparticles; Sali-NP-HER2, salinomycin-loaded polymer–lipid hybrid anti-HER2 nanoparticles.
Techniques Used: Proliferation Assay, Incubation, CCK-8 Assay, Cell Counting

Figure Legend Snippet: The IC 50 values of salinomycin and nanoparticles in breast cancer cells
Techniques Used:

Figure Legend Snippet: Effect of treatments on the percentage of CSCs. Notes: Effect of the treatments on the proportion of CSCs in breast cancer cells, as reflected by the tumorsphere formation rate ( A and B ) and the proportion of ALDH+ cells ( E and F ). Representative images of tumorspheres formed by ( C ) MDA-MB-361 cells and ( D ) BT-474 cells are shown. The rate of tumorsphere formation is defined as the number of tumorspheres formed in 7 days in the treatment group divided by the number of tumorspheres formed in 7 days in the untreated group; the rate of tumorsphere formation in the untreated group is used as a control and defined as 100%. The two groups were compared by one-way ANOVA with the Newman–Keuls method. Data are expressed as mean ± SD (n=6). * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: ANOVA, analysis of variance; ALDH, aldehyde dehydrogenase; CSCs, cancer stem cells; Sali-NP, salinomycin-loaded polymer–lipid nanoparticles; NP-HER2, polymer–lipid anti-HER2 nanoparticles; Sali-NP-HER2, salinomycin-loaded polymer–lipid hybrid anti-HER2 nanoparticles.
Techniques Used:

Figure Legend Snippet: In vivo antitumor assay in mice bearing subcutaneous BT-474 tumors. Notes: BT-474 tumors reached ~50 mm 3 in size by day 10. From day 10, mice were injected with nanoparticles (7.5 mg salinomycin/kg, i.v.) through the tail vein, and salinomycin (7.5 mg salinomycin/kg) dissolved in ethanol was administered by intraperitoneal injection. Therapy was given nine times on alternate days (indicated by arrows), and tumor volume was calculated. ( A ) Tumor growth curve. ( B ) Excised tumors. ( C ) The excised tumors were weighed at the end point. On day 28, the effect of the drug treatments on the CSC proportion in BT-474 tumors in vivo was evaluated by ( D ) the rate of tumorsphere formation and ( E ) the proportion of ALDH+ cells from the excised tumors. ( F ) Representative images of tumorspheres from ( D ) are shown. The two groups were compared by one-way ANOVA with the Newman–Keuls method. Data are expressed as mean ± SD (n=8). * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: ANOVA, analysis of variance; ALDH, aldehyde dehydrogenase; CSC, cancer stem cell; i.v., intravenous; Sali-NP, salinomycin-loaded polymer–lipid nanoparticles; NP-HER2, polymer–lipid anti-HER2 nanoparticles; Sali-NP-HER2, salinomycin-loaded polymer–lipid hybrid anti-HER2 nanoparticles.
Techniques Used: In Vivo, Injection
human bt474 breast cancer cell line (ATCC)


Structured Review

Human Bt474 Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human bt474 breast cancer cell line/product/ATCC
Average 95 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Phosphorylation of Ser 78 of Hsp27 correlated with HER-2/ neu status and lymph node positivity in breast cancer"
Article Title: Phosphorylation of Ser 78 of Hsp27 correlated with HER-2/ neu status and lymph node positivity in breast cancer
Journal: Molecular Cancer
doi: 10.1186/1476-4598-6-52

Figure Legend Snippet: Effect of heregulin α1 (HRG α1) and p38 MAPK inhibitor (SB 203580) on Hsp27 phosphorylation . Cultures of cells from the BT474 breast cancer cell line were treated with HRG α1 for 10 and 30 min (A) or SB 203580 for 10 hours (B) and total cell lysates were extracted using M-PER reagent (Pierce). Equal amounts of proteins (20 μg) were separated by SDS-PAGE and transferred onto PVDF membrane. The membranes were blocked for 1 hour, followed by being probed with the respective primary antibodies (anti-Hsp27, anti-pSer 15 , anti-pSer 78 and anti-pSer 82 ), and HRP-conjugated secondary antibody. The signals were captured and their intensities were detected as described in Figure 2. The phosphorylation levels of pSer 15 , pSer 78 and pSer 82 were expressed as the ratios of intensity probed with phosphorylation site-specific antibody to the intensity probed with anti-Hsp27. Data with ± SD represents the average of triplicate experiments. C: control; SB: inhibitor SB203580. For the control of HRG-treated cells, untreated cells were cultured for 10 and 30 min and equal amounts of cellular proteins from both time intervals were mixed and used as control. For the control of inhibitor-treated cells, cells were treated with DMSO for 10 hours and cellular proteins were used as the control. * p < 0.05 (student t -test)
Techniques Used: SDS Page, Cell Culture
human breast cancer cell lines bt 474 (ATCC)


Structured Review

Human Breast Cancer Cell Lines Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell lines bt 474/product/ATCC
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Targeted therapy against Bcl-2-related proteins in breast cancer cells"
Article Title: Targeted therapy against Bcl-2-related proteins in breast cancer cells
Journal: Breast Cancer Research
doi: 10.1186/bcr1323

Figure Legend Snippet: Expression levels of Bcl-2 and Bcl-xL proteins in MDA-MB-231, MDA-MD-453, BT-474, and ZR-75-1 cells. (a) Western blot analysis of Bcl-2 and Bcl-xL expression. (b) Quantification of Bcl-2 and Bcl-xL expression by densitometric analysis. The relative expression of Bcl-2 and Bcl-xL in MDA-MB-453 cells was compared with the expression in MDA-MB-231, BT-474, and ZR-75-1 cells. Results are from two representative, independent experiments.
Techniques Used: Expressing, Western Blot

Figure Legend Snippet: Sequence-specific downregulation and cytotoxic effects of antisense Bcl-2 oligodeoxynucleotides on BT-474 and ZR-75-1 cells. (a) Specific inhibition of Bcl-2 protein expression by treatment with antisense (AS) Bcl-2 oligodeoxynucleotides (ODNs). Cells were treated with 10 μg/ml Lipofectamine alone (control) or 1.0 μM AS, mismatch control (MM), or random control (RC) ODNs for 24 hours. Cells were then cultured in standard medium, total protein was extracted, and Bcl-2 and β-actin protein levels were analyzed by Western blotting. (b) Quantification of Bcl-2 expression by densitometric analysis. The expression of Bcl-2 in cells treated with control, AS Bcl-2 , RC Bcl-2 , and MM Bcl-2 ODNs was normalized with β-actin, and the relative values are presented. Error bars indicate SD. The data presented are from three independent experiments. (c) Effects of AS Bcl-2 ODNs on the proliferation of BT-474 and ZR-75-1 breast cancer cells in vitro . Cells were treated with various concentrations of AS Bcl-2 ODNs in 24-well dishes. Four days after treatment, cells were stained with trypan blue and counted. Error bars indicate SD. The data presented are from three independent experiments.
Techniques Used: Sequencing, Inhibition, Expressing, Cell Culture, Western Blot, In Vitro, Staining

Figure Legend Snippet: Effect of antisense Bcl-2 oligodeoxynucleotides on chemosensitivity in BT-474, ZR-75-1, and MDA-MB-231 breast cancer cells
Techniques Used:

Figure Legend Snippet: Sequence-specific downregulation and cytotoxic effects of antisense Bcl-xL oligodeoxynucleotides on MDA-MB-231 and BT-474 cells. (a) Specific inhibition of Bcl-xL protein expression by treatment with antisense (AS) Bcl-xL oligodeoxynucleotides (ODNs). Cells were treated with 10 μg/ml Lipofectamine alone (control) or 1.0 μM AS, mismatch control (MM), or random control (RC) ODNs for 24 hours. Cells were then cultured in standard medium, total protein was extracted, and Bcl-xL and β-actin protein levels were analyzed by Western blotting. (b) Quantification of Bcl-xL protein expression by densitometric analysis. The Bcl-xL protein expression was normalized with β-actin, and the relative values are presented. Error bars indicate SD. The data presented are from three independent experiments. (c) Effects of AS Bcl-xL ODNs on the proliferation of MDA-MB-231 and BT-474 breast cancer cells in vitro . Cells were treated with various concentrations of AS Bcl-xL ODNs in 24-well dishes. Four days after treatment, cells were stained with trypan blue and counted. Error bars indicate SD. The data presented are from three independent experiments.
Techniques Used: Sequencing, Inhibition, Expressing, Cell Culture, Western Blot, In Vitro, Staining

Figure Legend Snippet: Effect of antisense Bcl-xL oligodeoxynucleotides on chemosensitivity in BT-474, ZR-75-1, and MDA-MB-231 breast cancer cells
Techniques Used:

Figure Legend Snippet: Effects of treatment with antisense Bcl-2 and mitomycin C, doxorubicin, paclitaxel, or docetaxel on BT-474 cells. (a) Expression levels of Bcl-2 and Bcl-xL protein in BT-474 cells transplanted into athymic mice after treatment with antisense (AS) Bcl-2 oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. (b) Enhancement of the antitumor effects of anticancer drugs by AS Bcl-2 ODNs in BT-474 tumor xenografts. Each point represents the mean tumor volume of the eight mice in each group. Error bars indicate SD. *, P < 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxorubicin; TXL, paclitaxel; TXT, docetaxel.
Techniques Used: Expressing, Western Blot

Figure Legend Snippet: Effect of synthetic CpG antisense Bcl-2 on BT-474 cells in comparison with antisense Bcl-2 . Each point represents the mean tumor volume of the four mice in each group. Error bars indicate SD. The data presented are from two independent experiments. RC, random control; TXT, docetaxel.
Techniques Used:
human breast cancer cell lines bt 474 (ATCC)


Structured Review
![Plot of the (total/bound) activity versus (1/[normalized cell concentration]), used to calculate the immunoreactivity fraction of 89 Zr-DFO-trastuzumab in <t>BT-474</t> (HER2/ neu positive) cells by extrapolation to infinite antigen excess (1/ y -intercept).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0330/pmc02810330/pmc02810330__pone.0008859.g001.jpg)
Human Breast Cancer Cell Lines Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell lines bt 474/product/ATCC
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/ neu Expression in Mice Using 89 Zr-DFO-Trastuzumab"
Article Title: Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/ neu Expression in Mice Using 89 Zr-DFO-Trastuzumab
Journal: PLoS ONE
doi: 10.1371/journal.pone.0008859
![... calculate the immunoreactivity fraction of 89 Zr-DFO-trastuzumab in BT-474 (HER2/ neu positive) cells by extrapolation to infinite ... Plot of the (total/bound) activity versus (1/[normalized cell concentration]), used to calculate the immunoreactivity fraction of 89 Zr-DFO-trastuzumab in BT-474 (HER2/ neu positive) cells by extrapolation to infinite antigen excess (1/ y -intercept).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0330/pmc02810330/pmc02810330__pone.0008859.g001.jpg)
Figure Legend Snippet: Plot of the (total/bound) activity versus (1/[normalized cell concentration]), used to calculate the immunoreactivity fraction of 89 Zr-DFO-trastuzumab in BT-474 (HER2/ neu positive) cells by extrapolation to infinite antigen excess (1/ y -intercept).
Techniques Used: Activity Assay, Concentration Assay

Figure Legend Snippet: Biodistribution data of 89 Zr-DFO-trastuzumab versus time/h, administered by i.v. tail-vein injection to female, athymic nu / nu mice bearing s.c. BT-474 tumors (90–150 mm 3 ).
Techniques Used: Injection

Figure Legend Snippet: Bar charts showing selected tissue biodistribution data (%ID/g) for (A) uptake of high and low specific-activity formulations of 89 Zr-DFO-trastuzumab in BT-474 tumor-bearing mice, and (B) 89 Zr-DFO-trastuzumab uptake in control (vehicle-treated) and PU-H71 treated animals at 12, 24, 48 and 72 h post-i.v. administration of 89 Zr-DFO-trastuzumab (0.55–0.74 MBq, 5–7 µg of mAb, in 200 µL 0.9% sterile saline).
Techniques Used: Activity Assay

Figure Legend Snippet: Pharmacodynamic studies on protein expression levels in BT-474 tumor tissue samples obtained at 12, 24, 48, 72 and 96 h after PU-H71 treatment.
Techniques Used: Expressing

Figure Legend Snippet: Time-activity curves derived by region-of-interest analysis of the immunoPET images showing the mean %ID/g tissue uptake versus time/h, for control and PU-H71-treated mice bearing both BT-474 and MDA-MB-468 tumors.
Techniques Used: Activity Assay, Derivative Assay
human breast cancer cell line bt474 (ATCC)


Structured Review

Human Breast Cancer Cell Line Bt474, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell line bt474/product/ATCC
Average 95 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib"
Article Title: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Journal: Breast Cancer Research : BCR
doi: 10.1186/bcr2936

Figure Legend Snippet: Phosphorylated levels of β1 downstream kinases are increased upon acquisition of resistance to lapatinib (L) . ( A ) Parental (P) BT474 and ( B ) HCC1954 cells resistant to lapatinib (LRes), trastuzumab (TRes), and combination (LTRes) treatment strategies were developed by long-term exposure in 2D. Protein extracts were probed for β1, pHER2, pFAK, and pSrc, as well as totals.
Techniques Used:

Figure Legend Snippet: β1 blockade overcomes lapatinib resistance in BT474 cells in 3D culture . ( A ) Parental and LRes cells were plated on lrECM and treated ± lapatinib. ( B ) The β1 inhibitory antibody AIIB2--or IgG control--was applied to parental and LRes cells on Day 0 of plating on lrECM and allowed to grow for 12 days. ( C ) Parental and LRes cells were plated in lrECM with appropriate inhibitors, allowed to grow for five days, stained with Ki67 antigen or TUNEL labeling, and imaged. ( D ) 3D cultures of BT474 parental and LRes cells treated with AIIB2 or IgG were allowed to propagate for five days, then harvested for protein and immunoblotting. Densitometry measurements were normalized to total levels--except β1, which was normalized to β-actin--and are representative of three independent experiments. ( E ) The FAK inhibitor PF 573228 was applied to parental and LRes cells on Day 0 of plating on lrECM and cultures were allowed to grow for 12 days.
Techniques Used: Staining, TUNEL Assay, Labeling, Western Blot

Figure Legend Snippet: Percent growth inhibition of cells in response to HER-targeted therapies
Techniques Used: Inhibition

Figure Legend Snippet: HER2 and the β1 pathway play alternate roles in resistance to lapatinib-containing regimens, in comparison to trastuzumab . ( A ) Parental, LRes, and TRes cells were plated on lrECM in the presence of lapatinib and/or trastuzumab and assayed for response. ( B ) 3D cultures of parental, LRes, and TRes BT474 cells were harvested for protein and probed for phosphorylated and total HER receptors.
Techniques Used:

Figure Legend Snippet: β1 inhibition impedes colony grow of BT474 LRes and LTRes cells, but not parental or TRes . ( A ) Parental, LRes, LTRes, and TRes cells were plated in lrECM, subjected to HER2 and/or β1 inhibitors on Day 0, and propagated for 10 to 12 days. ( B ) The Hs_ITGB1_5 siRNA was validated both in 2D and 3D (top), transfected at 40 nMsi into parental, LRes, LTRes, and TRes cells, which were then grown on lrECM for 10 days (bottom).
Techniques Used: Inhibition, Transfection
human breast cancer cell line bt (ATCC)


Structured Review

Human Breast Cancer Cell Line Bt, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell line bt/product/ATCC
Average 95 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells"
Article Title: FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells
Journal: Oncoscience
doi:

Figure Legend Snippet: A. Effects of FS-93 on cell proliferation. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 72 h. Cell viability was assessed with SRB assay. Bars represent means±SD. B. Effects of FS-93 on degradation of client onco-proteins. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 24 h. Cell lysates were prepared and analyzed with immunoblotting.
Techniques Used: Sulforhodamine B Assay, Western Blot

Figure Legend Snippet: A ., B. Effects of FS-93 on cell cycle distribution. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 24 h. Cell cycle distribution was analyzed by FACS after propidium iodide staining. Representative images A. and quantification results B. were presented. Bars represent means±SD. C. Impacts of FS-93 on G2/M transition regulators. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 24 h and cells lysates were immunoblotted with the indicated antibodies.
Techniques Used: Staining

Figure Legend Snippet: A. Effects of FS-93 on apoptosis induction. BT-474, NCI-H3122 and EBC-1 cells were treated with DMSO or FS-93 at 100 nM for 12, 24, 48 and 72h. Apoptosis was determined with annexin-V/PI assay. Bars represent means±SD. B. Impacts of FS-93 on apoptotic proteins. BT-474 cells were treated with DMSO or FS-93 at 100 nM for 12, 24, 48 and 72h and analyzed by immunoblotted with the indicated antibodies.
Techniques Used:
human breast cancer cell line bt 474 (ATCC)


Structured Review
![Brusatol regressed the growth of HER2-positive SK-OV-3, <t>BT-474,</t> and SK-BR-3 cells by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. (a) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol in a dose range for 2 days. IC50 for BT-474, SK-OV-3, and SK-BR-3 were 0.7537 μ M (95% confidence interval [CI], 0.6983–0.8136 μ M), 0.7610 μ M (95% CI, 0.6699–0.8646 μ M), 8.631 μ M (95% CI, 7.699–9.675 μ M), respectively. Points, mean of 3 independent CCK-8 assays; bars, SD. (b) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol at 0, 1, 5, or 10 μ M for 24 hours. The changes in Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling pathways were monitored by western blotting.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7975/pmc07387975/pmc07387975__OMCL2020-9867595.001.jpg)
Human Breast Cancer Cell Line Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell line bt 474/product/ATCC
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways"
Article Title: Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
Journal: Oxidative Medicine and Cellular Longevity
doi: 10.1155/2020/9867595
![Brusatol regressed the growth of HER2-positive SK-OV-3, BT-474, and SK-BR-3 cells by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 ... Brusatol regressed the growth of HER2-positive SK-OV-3, BT-474, and SK-BR-3 cells by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. (a) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol in a dose range for 2 days. IC50 for BT-474, SK-OV-3, and SK-BR-3 were 0.7537 μ M (95% confidence interval [CI], 0.6983–0.8136 μ M), 0.7610 μ M (95% CI, 0.6699–0.8646 μ M), 8.631 μ M (95% CI, 7.699–9.675 μ M), respectively. Points, mean of 3 independent CCK-8 assays; bars, SD. (b) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol at 0, 1, 5, or 10 μ M for 24 hours. The changes in Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling pathways were monitored by western blotting.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7975/pmc07387975/pmc07387975__OMCL2020-9867595.001.jpg)
Figure Legend Snippet: Brusatol regressed the growth of HER2-positive SK-OV-3, BT-474, and SK-BR-3 cells by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. (a) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol in a dose range for 2 days. IC50 for BT-474, SK-OV-3, and SK-BR-3 were 0.7537 μ M (95% confidence interval [CI], 0.6983–0.8136 μ M), 0.7610 μ M (95% CI, 0.6699–0.8646 μ M), 8.631 μ M (95% CI, 7.699–9.675 μ M), respectively. Points, mean of 3 independent CCK-8 assays; bars, SD. (b) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol at 0, 1, 5, or 10 μ M for 24 hours. The changes in Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling pathways were monitored by western blotting.
Techniques Used: CCK-8 Assay, Western Blot

Figure Legend Snippet: Brusatol exhibited antitumor activity in combination with trastuzumab in a synergistic manner on HER2-positive BT-474 and SK-OV-3 cells. (a) BT-474, SK-OV-3, and SK-BR-3 cells were treated with trastuzumab and brusatol as single agents and in combination with trastuzumab in a dose range for 2 days. Points, mean of 3 independent CCK-8 assays; bars, SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (b) The synergistic effect of trastuzumab in combination with brusatol was evaluated on the growth of BT474, SK-OV-3, or SK-BR-3 cell line. Combination index (CI) values were calculated at the drug concentration of trastuzumab (12.5 μ g/mL) plus brusatol (2.5 μ M), trastuzumab (25 μ g/mL) plus brusatol (5 μ M), and trastuzumab (50 μ g/mL) plus brusatol (10 μ M) using the Chou-Talalay method. Drug synergy, addition, and antagonism are defined by CI values less than 1.0, equal to 1.0, or greater than 1.0, respectively.
Techniques Used: Activity Assay, CCK-8 Assay, Concentration Assay

Figure Legend Snippet: Trastuzumab plus brusatol potently inhibited the activation of Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. (a, b) BT-474 and SK-OV-3 cells were treated with trastuzumab or brusatol alone, or their combination for 24 hours. The changes in Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling pathways were monitored by western blotting. (c, d) Densitometric analysis was performed on the western blotting. The levels of Nrf2, HO-1, p-HER2, p-AKT, and p-ERK1/2 were quantified by using the software Image J. The data are expressed as the mean ± SD of three independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Techniques Used: Activation Assay, Western Blot, Software

Figure Legend Snippet: Trastuzumab in combination with brusatol effectively enhanced ROS accumulation in BT-474 and SK-OV-3 cells. (a) BT-474 were treated with control IgG (25 μ g/mL), trastuzumab (25 μ g/mL), brusatol (5 μ M), or trastzumab (25 μ g/mL) plus brusatol (5 μ M) for 24 h, and flow cytometry was used to analyze the level of ROS in cells after DCFH-DA was added to stain the cells. Bar graphic representations of the fluorescence intensity upon different treatments relative to control were shown. Data was presented as mean ± SD. (b) SK-OV-3 cells were treated with control IgG (25 μ g/mL), trastuzumab (25 μ g/mL), brusatol (5 μ M), or trastzumab (25 μ g/mL) plus brusatol (5 μ M), and flow cytometry was used to analyze the level of ROS in cells after DCFH-DA was added to stain the cells. Bar graphic representations of the fluorescence intensity upon different treatments relative to control were shown. Data was presented as mean ± SD.
Techniques Used: Flow Cytometry, Staining, Fluorescence

Figure Legend Snippet: Trastuzumab in combination with brusatol potently induced apoptosis in BT-474 and SK-OV-3 cancer cells. (a) Induction of apoptosis of BT-474 cells after control IgG (25 μ g/mL), brusatol (5 μ M), trastuzumab (25 μ g/mL), or the combinatorial treatment for 48 h. Apoptosis ratios were measured by flow cytometry. Data was shown with mean ± SD of three independent experiments. ∗∗∗ p < 0.001. (b) Induction of apoptosis of SK-OV-3 cells after control IgG (25 μ g/mL), brusatol (5 μ M), trastuzumab (25 μ g/mL), or the combinatorial treatment for 48 h. Apoptosis ratios were measured by flow cytometry. Data was shown with mean ± SD of three independent experiments. ∗∗∗ p < 0.001.
Techniques Used: Flow Cytometry

Figure Legend Snippet: Trastuzumab caused tumor regression in BT-474 and SK-OV-3 xenografts in combination with brusatol. (a) Mean tumor volume of SK-OV-3 xenografts after injection with control IgG (15 mg/kg), trastuzumab (15 mg/kg), brusatol (2 mg/kg), or trastuzumab (15 mg/kg) plus brusatol (2 mg/kg). (b) On day 15 postfirst injection, xenograft tumors from each group were removed and tumor masses were weighed. (c) Effects of trastuzumab, brusatol or trastzuamb plus brusatol on tumor-bearing mice body weight were determined using SK-OV-3 tumor-bearing nude mice. Mice were weighed at regular intervals during the whole period to monitor unspecific toxicity. (d) Mean tumor volume of BT-474 xenografts after injection with control IgG (15 mg/kg), trastuzumab (15 mg/kg), brusatol (2 mg/kg), or trastuzumab (15 mg/kg) plus brusatol (2 mg/kg). (e) On day 17 postfirst injection, xenograft tumors from each group were removed and tumor masses were weighed. (f) Effects of trastuzumab, brusatol or trastzuamb plus brusatol on tumor-bearing mice body weight were determined using BT-474 tumor-bearing nude mice. Mice were weighed at regular intervals during the whole period to monitor unspecific toxicity. Data are shown asa mean ± SD. ( n = 5 mice, each group); ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001.
Techniques Used: Injection
human breast cancer cell line bt 474 (ATCC)


Structured Review

Human Breast Cancer Cell Line Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell line bt 474/product/ATCC
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG 2a -f) Exerts Antitumor Activity in Xenograft Model"
Article Title: A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG 2a -f) Exerts Antitumor Activity in Xenograft Model
Journal: Antibodies
doi: 10.3390/antib11040074

Figure Legend Snippet: Flow cytometric analyses. ( A ) BT-474 and Capan-2 cells were treated with 10 µg/mL of EpMab-37-mG 2a -f (red line) or blocking buffer as a negative control (black line), followed by addition of Alexa Fluor 488-conjugated anti-mouse IgG. Data were collected using the EC800 Cell Analyzer. ( B ) BT-474 and Capan-2 cells were suspended in 100 μL of serially diluted EpMab-37-mG 2a -f (0.006–100 μg/mL), followed by the addition of Alexa Fluor 488-conjugated anti-mouse IgG. Data were collected using the BD FACS Lyric and analyzed by GraphPad PRISM 9 to determine the apparent dissociation constant ( K D ).
Techniques Used: Blocking Assay, Negative Control

Figure Legend Snippet: Evaluation of EpMab-37-mG 2a -f mediated ADCC and CDC activities in BT-474 and Capan-2 cells. ( A , C ) ADCC elicited by EpMab-37-mG 2a -f or control mouse IgG 2a against BT-474 ( A ) and Capan-2 ( C ) cells. ( B , D ) CDC elicited by EpMab-37-mG 2a -f or control mouse IgG 2a against BT-474 ( B ) and Capan-2 ( D ) cells. Values are shown as mean ± SEM. Asterisks indicate statistical significance (** p < 0.01, * p < 0.05; Welch’s t -test). ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity.
Techniques Used:

Figure Legend Snippet: ADCC reporter assay by EpMab-37-mG 2a -f and 281-mG 2a -f in the presence of BT-474 and Capan-2 cells. ( A , B ) Target cells (BT-474 ( A ) and Capan-2 ( B )) were treated with serially diluted EpMab-37-mG 2a -f and 281-mG 2a -f (mouse IgG 2a control). Then, Jurkat cells stably expressing the human FcγRIIIa receptor and an NFAT response element driving firefly luciferase were added and co-cultured. Luminescence was measured using the Bio-Glo Luciferase Assay System. ADCC, antibody-dependent cellular cytotoxicity.
Techniques Used: Reporter Assay, Stable Transfection, Expressing, Luciferase, Cell Culture

Figure Legend Snippet: Antitumor activity of EpMab-37-mG 2a -f. ( A , B ) Measurement of tumor volume in ( A ) BT-474 and ( B ) Capan-2 xenograft models. BT-474 and Capan-2 cells (5 × 10 6 cells) were inoculated into mice subcutaneously. On day six, 100 μg of EpMab-37-mG 2a -f or control mouse IgG were injected into mice intraperitoneally. On day 13 and 18 (BT-474) or 14 and 18 (Capan-2), additional antibodies were injected. On the indicated days after the inoculation, the tumor volume was measured. Values are presented as the mean ± SEM. ** p < 0.01, * p < 0.05 (ANOVA and Sidak’s multiple comparisons test). ( C , D ) The weight of excised ( C ) BT-474 and ( D ) Capan-2 xenografts was measured on day 24 and 27, respectively. Values are presented as the mean ± SEM. ** p < 0.01 (Welch’s t test). ( E , F ) The resected tumors appearance of ( E ) BT-474 and ( F ) Capan-2 xenografts in the control mouse IgG and EpMab-37-mG 2a -f treated groups on day 24 and 27, respectively (scale bar, 1 cm). n.s., not significant.
Techniques Used: Activity Assay, Injection

Figure Legend Snippet: Mice body weights and appearance. ( A , B ) Body weights in ( A ) BT-474 and ( B ) Capan-2 xenografts-implanted mice on the indicated days (ANOVA and Sidak’s multiple comparisons test). ( C , D ) Body appearance in ( C ) BT-474 and ( D ) Capan-2 xenografts-implanted mice on day 24 and 27, respectively (scale bar, 1 cm). n.s., not significant.
Techniques Used:
human breast cancer cell lines bt 474 (ATCC)


Structured Review
Human Breast Cancer Cell Lines Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human breast cancer cell lines bt 474/product/ATCC
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99